With the approval, Eli Lilly’s Mounjaro becomes the first dual GIP/GLP-1 receptor agonist indicated to lower the risk of ...

Teva Pharmaceuticals is the 'stalking horse bidder' to kick off the auction process for BioXcel Therapeutics' AI-derived ...

Shares of Germany-based BioNTech were down as much as 8% Friday after announcing a Phase 2 trial of autogene cevumeran would ...

Lisraya carries a boxed warning typical of JAK inhibitors, but otherwise has a broad label that allows use in all adults with ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

Even without specific Phase 3 data yet revealed, analysts see AstraZeneca and Amgen’s Tezspire as a potential threat for ...

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...

AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

Haisco Pharmaceutical Group has been on a deal hot streak this year, inking major deals with Eli Lilly, AbbVie and more. The ...

Thanks in part to the revolution cell therapy brought to treating blood cancers, the modality is now showing promise in some ...

Manufacturers are being pushed beyond mAb‑era platforms into a new design model built around molecular engineering, complex ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...